Ophthalmic Drugs Market Size is Generating Revenue of $58.13 Billion by 2027 | Dry Eye, Anti-infection, Anti-inflammation, Drugs

Alarming increase in prevalence of ophthalmic disorders across the globe, advancements in research and development for manufacturing of combinational therapies for the treatment of ophthalmic disorder, and surge in geriatric population are expected to notably contribute toward the growth of the global ophthalmic drugs market during the forecast period.

The global ophthalmic drugs market was valued at $36.49 billion in 2019, and is projected to reach $58.13 billion by 2027, registering a CAGR of 5.6% from 2020 to 2027.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/310

The eye is one of the most sensitive organs of the human body. Ophthalmic drug formulations are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD).

COVID-19 scenario-

1) The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.

2) The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.

3) However, as the world has been recovering from the pandemic, the market is estimated to get back on track.

The development of effective ophthalmic drugs has become essential, owing to increase in incidence of ophthalmic disorders such as glaucoma, cataract, and other common eye infections. Ophthalmic drugs are administered in different dosage forms depending on indication. Market players are focusing on the development of novel approaches for the development of ophthalmic drugs over the years, including small molecule, biologic, and recombinant technologies. Increase in focus on developing combination therapies for the treatment of ophthalmic disorders, the prevalence of ophthalmic disorders, and a rise in geriatric population are anticipated to drive the growth of the ophthalmic drugs market. In addition, increase in the changing demographics across the globe supplement the market growth.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/310

The implementation of lockdown due to COVID-19 outbreak has delayed the treatment for ophthalmic disorder up to six months; thereby, having a minimal negative impact on the market. Due to COVID-19 pandemic, many hospitals across the globe, were restructured to increase the hospital capacity for the patient diagnosed with COVID-19. This leads to cancellation of many non-essential surgical procedures. Also, the quality of care toward the patients other than COVID-19 decreased.

The ophthalmic drugs market is segmented into indication, type, dosage form, distribution channel, and therapeutic class. On the basis of indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorder, and others. The retinal disorders segment dominated the market in 2019, due to rise in prevalence or macular degeneration, increasing in number of geriatric population and increase in health education initiatives taken by government about eye diseases to seek early treatment and prevent visual impairment occurring due to retinal disorders. The retinal disorders segment is further divided into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others.

Depending on type, the market is categorized into prescription drugs and over-the-counter-drugs. The prescription drugs spearheaded the market in 2019, which is attributed to the fact that majority of the drugs administered for the treatment of eye diseases are taken by the patients only after consulting their doctors. By dosage form, the ophthalmic drugs market is segregated into a liquid ophthalmic drug forms, solid ophthalmic drug forms, semi-solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. The liquid ophthalmic drug forms is expected to lead the market during the study period, due to increase in demand for liquid dosage form by the patient and the increasing in number of manufacturing of ophthalmic drug in liquid dosage form.

Download Detailed COVID-19 Impact Sample Report at @ https://www.alliedmarketresearch.com/request-for-customization/310?reqfor=covid

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores, online pharmacies, and others. The hospital pharmacies segment led the market in 2019, and is expected to continue this trend throughout the forecast period, due to increase in prevalence of chronic eye ailments such as glaucoma, cataract, and retinal disorders.

By application, the market is studies across anti-glaucoma, anti-infection, anti-inflammation, anti-allergy and others. The anti-inflammatory is expected to exhibit the highest growth throughout the forecast period, owing to rise in prevalence of allergic conjunctivitis and hypersensitivity reactions.

The major companies profiled Are:

• Santen Pharmaceutical Co., Ltd.
• Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.)
• Shire Plc
• Alcon (Novartis)
• Genentech, Inc.
• Allergan, Plc
• Sun Pharmaceutical Industries Limited
• Actavis Generics (Teva Pharmaceutical Industries Ltd.)
• Regeneron Pharmaceuticals, Inc.
• Pfizer Inc.

Access Full Report @ https://www.alliedmarketresearch.com/ophthalmic-drugs-market

Key Findings Of The Study:

• By indication, the retinal disorders segment was the highest contributor to the ophthalmic drugs market in 2019
• By type, the prescription drugs segment dominated the market in 2019 and is expected to continue this trend throughout the review period
• By dosage form, the liquid ophthalmic drug forms segment led the market in 2019
• By distribution channel, the hospital pharmacies segment led the market in 2019
• By therapeutic class, the anti-inflammatory segment will exhibit considerable growth from 2020 to 2027
• By region, North America garnered largest revenue share in 2019, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the review period.

Similar Reports:

Hydrogel Dressing Market : https://www.einpresswire.com/article/528462671/hydrogel-dressing-market-to-witness-robust-expansion-throughout-the-forecast-2020-2027

Anti-Viral Therapies Market : https://www.einnews.com/pr_news/528465419/antiviral-therapies-market-our-look-at-the-biggest-trends-hitting-the-industry-over-the-coming-12-months

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.